Professsional - Overview

Chronic Disease and Diabetes Involves Multi-Disciplinary Healthcare Professionals

Healthcare professionals are involved in the detection, monitoring, management and treatment of chronic disease conditions and diabetes. 

In the U.S. there are about 25.8 million people with diabetes and another estimated 79 million with pre-diabetes. The CDC has declared diabetes at epidemic levels in the United States. The World Health Organization estimates 220 million people live with diabetes worldwide today and will more than double by 2030.

Freedom Meditech is a private, growth-stage medical device company focused on the development and commercialization of first-to-market, non-invasive, ophthalmic medical devices that detect autofluorescence of the lens (ClearPath DS-120) and help monitor diabetes (I-SugarX).

The hallmark of our product portfolio is to provide free, healthy, and cost-effective alternatives to existing diagnostic tools on the market for the detection, monitoring and management of chronic diseases.

Our current offering includes:

ClearPath DS-120 Lens Fluorescence Biomicroscope

The ClearPath DS-120 received 510(k) market clearance from the United States Food and Drug Administration,  effective January 31, 2013.

The ClearPath DS-120 is a proprietary non-invasive ophthalmic measurement tool that detects autofloresence of the crystalline lens of the eye. In independent scientific studies published in peer-reviewed journals, elevated autofluorescence measurements have been linked to high levels of advanced glycosylated end products which accumulate as a result of the aging process and the presence of systemic disease. This bio-photonic approach is appealing to healthcare providers and patients because the test is:

Non-Invasive - There is no need for dialation, blood draw, or other patient preparation

Quick - the test begins and ends within six seconds

Immediate - Quantitative results are provided at the point of care with no need to wait several days test results

Reliable - Has demonstrated a Repeatability and Reproducibility error of only 5.8 % and 6.4% respectively, which is more precise than comparable standard of care ophthalmic devices widely utilized by health care providers today.

No Hassle - No fasting is required by the patient and no biohazard waste is generated that requires disposal by the clinican

I-SugarX™ Glucose Monitoring for Diabetes

The I-SugarX™ is an investigational device not yet approved for market or sale in the United States

The I-SugarX™, is a rapid non-invasive, point of care, personal glucose meter that is operated by holding the small handheld device in front of the eye similar to a miniature telescope. The I-SugarX™ is planned to offer many benefits over the existing “finger prick”glucose test. The benefits include:

Direct measurement of glucose in aqueous

Painless

Easy to use no prick no blood or bio waste

Personalized glucose meter point of care

Convenient

Each test is calibrated ensuring quality reading

Easy to read large number display

Readings over time are captured and retained for computer down load:

Tracks patient compliance

Trending data

Multiple test provide trend for better therapeutic decisions

Out of control glucose excursions correlation with therapy